» Articles » PMID: 17322912

From Tpr-Met to Met, Tumorigenesis and Tubes

Overview
Journal Oncogene
Date 2007 Feb 27
PMID 17322912
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

The receptor for hepatocyte growth factor (HGF)/scatter factor (SF), Met, controls a program of invasive epithelial growth through the coordination of cell proliferation and survival, cell migration and epithelial morphogenesis. This process is important during embryogenesis and for organ regeneration in the adult. However, when deregulated the HGF/SF-Met signaling axis contributes to tumorigenesis and metastasis. Studies on the oncogenic activation of the Met receptor have shed light on the molecular mechanisms underlying the oncogenic activation of receptor tyrosine kinase (RTKs). More than a decade ago, work on the Met related oncogene, Tpr-Met, revealed the mechanism for activation of RTK-derived oncogenes generated following chromosomal translocation. More recently, studies on the mechanisms of downregulation of the Met RTK highlight a role for loss of downregulation in RTK oncogenic activation.

Citing Articles

Signaling pathways in liver cancer: pathogenesis and targeted therapy.

Xue Y, Ruan Y, Wang Y, Xiao P, Xu J Mol Biomed. 2024; 5(1):20.

PMID: 38816668 PMC: 11139849. DOI: 10.1186/s43556-024-00184-0.


Clinical, pathologic, and genomic characteristics of two pediatric glioneuronal tumors with a CLIP2::MET fusion.

Chapman N, Greenwald J, Suddock J, Xu D, Markowitz A, Humphrey M Acta Neuropathol Commun. 2024; 12(1):63.

PMID: 38650040 PMC: 11036580. DOI: 10.1186/s40478-024-01776-1.


Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma.

Zeng M, Liu C, Gong H, Tang Z, Wen J, Wang S Front Mol Biosci. 2024; 11:1367331.

PMID: 38596618 PMC: 11002252. DOI: 10.3389/fmolb.2024.1367331.


Aberrant Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions.

Al-Ghabkari A, Huang B, Park M Cells. 2024; 13(3.

PMID: 38334610 PMC: 10854665. DOI: 10.3390/cells13030218.


Compounds originating from the edible mushroom inhibit tropomyosin receptor kinase B activity.

Shahar O, Pereman I, Khamisie H, Ezov N, Danay O, Khattib A Heliyon. 2023; 9(3):e13756.

PMID: 36895384 PMC: 9988514. DOI: 10.1016/j.heliyon.2023.e13756.